,3 First-line and relapse therapy are constantly developed for AML and include antibody-drug conjugate (ADC) gemtuzumab ozogamicin targeting CD33; monoclonal antibodies (mAbs) targeting CD44; and CD123, bi-specific T cell engagers (BiTEs) or immune checkpoint inhibitors.4 Here, CD33 is linked to acute myeloid leukemia.